News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
714,532 Results
Type
Article (43114)
Company Profile (340)
Press Release (671078)
Section
Business (214165)
Career Advice (2119)
Deals (37119)
Drug Delivery (99)
Drug Development (83488)
Employer Resources (173)
FDA (16658)
Job Trends (15651)
News (360877)
Policy (34224)
Tag
Academia (2683)
Alliances (53094)
Alzheimer's disease (1259)
Approvals (16569)
Artificial intelligence (131)
Bankruptcy (366)
Best Places to Work (11851)
Biotechnology (221)
Breast cancer (110)
Cancer (935)
Cardiovascular disease (84)
Career advice (1770)
Cell therapy (209)
Clinical research (65949)
Collaboration (347)
Compensation (169)
COVID-19 (2641)
Data (858)
Diabetes (134)
Diagnostics (6288)
Drug pricing (90)
Earnings (86310)
Employer resources (151)
Events (113882)
Executive appointments (249)
FDA (17110)
Funding (298)
Gene therapy (157)
GLP-1 (606)
Government (4533)
Healthcare (19334)
Infectious disease (2715)
Inflammatory bowel disease (109)
Interviews (330)
IPO (16720)
Job creations (4108)
Job search strategy (1516)
Layoffs (434)
Legal (8404)
Lung cancer (161)
Manufacturing (164)
Medical device (13475)
Medtech (13480)
Mergers & acquisitions (20398)
Metabolic disorders (380)
Neuroscience (1510)
NextGen Class of 2024 (6893)
Non-profit (4703)
Northern California (1217)
Obesity (226)
Opinion (209)
Patents (100)
People (59031)
Pharmaceutical (94)
Phase I (20404)
Phase II (29011)
Phase III (21791)
Pipeline (209)
Postmarket research (2651)
Preclinical (8686)
Radiopharmaceuticals (245)
Rare diseases (190)
Real estate (6386)
Regulatory (22515)
Research institute (2452)
Resumes & cover letters (367)
Southern California (1089)
Startups (3862)
United States (11887)
Vaccines (578)
Weight loss (176)
Date
Today (169)
Last 7 days (824)
Last 30 days (2858)
Last 365 days (36840)
2024 (31242)
2023 (41212)
2022 (52459)
2021 (57010)
2020 (55654)
2019 (48611)
2018 (36732)
2017 (33765)
2016 (33350)
2015 (39355)
2014 (33114)
2013 (28151)
2012 (30189)
2011 (30943)
2010 (28910)
Location
Africa (802)
Arizona (196)
Asia (40914)
Australia (6555)
California (2762)
Canada (1177)
China (214)
Colorado (121)
Connecticut (124)
Europe (87954)
Florida (398)
Georgia (99)
Illinois (323)
Indiana (186)
Kansas (96)
Maryland (526)
Massachusetts (2251)
Michigan (143)
Minnesota (255)
New Jersey (832)
New York (841)
North Carolina (719)
Northern California (1217)
Ohio (126)
Pennsylvania (747)
South America (1189)
Southern California (1089)
Texas (393)
Washington State (333)
714,532 Results for "catalyst pharmaceutical partners inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States
Santhera Pharmaceuticals is pleased to note the launch of AGAMREE® for the treatment of Duchenne muscular dystrophy in the United States by Catalyst Pharmaceuticals, Inc., the Company’s commercialization partner for North America.
March 14, 2024
·
5 min read
Catalyst Pharmaceuticals to Participate at the Jefferies Global Healthcare Conference 2024
Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst’s management team, will participate at the upcoming Jefferies Global Healthcare Conference 2024 on Wednesday, June 5, 2024, in New York.
May 28, 2024
·
3 min read
Catalyst Pharmaceuticals Receives U.S. FDA Approval For Increased Maximum Daily Dose For FIRDAPSE®
Catalyst Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (“FDA”) has approved its supplemental New Drug Application (“sNDA”) increasing the indicated maximum daily dose of FIRDAPSE.
May 30, 2024
·
4 min read
Catalyst Pharmaceuticals to Participate at the BofA Securities Health Care Conference 2024
Catalyst Pharmaceuticals, Inc. today announced that Richard J. Daly, President and CEO of Catalyst, along with other members of Catalyst’s management team, will participate at the upcoming BofA Securities Health Care Conference.
May 1, 2024
·
3 min read
Business
Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update
Catalyst Pharmaceuticals, Inc. (“Catalyst” or “Company”) (Nasdaq: CPRX) today reported financial results for the first quarter of 2024 and provided a business update.
May 8, 2024
·
12 min read
Catalyst Pharmaceuticals to Participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium
Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX) today announced that Richard J. Daly, CEO of Catalyst, along with other members of Catalyst’s management team, will participate in the 2024 Cantor Virtual Muscular Dystrophy Symposium taking place virtually on April 2-3, 2024.
March 27, 2024
·
3 min read
Business
Catalyst Pharmaceuticals Announces FIRDAPSE® New Drug Application Submitted in Japan by Partner DyDo Pharma
Catalyst Pharmaceuticals, Inc. today announced that its collaboration partner, DyDo Pharma, Inc. (“DyDo”), reported that it has submitted a New Drug Application (“NDA”) to Japan’s Pharmaceuticals and Medical Devices Agency (“PMDA”) seeking marketing approval for FIRDAPSE.
December 18, 2023
·
5 min read
Press Releases
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
October 23, 2024
·
2 min read
Business
Catalyst Pharmaceuticals to Report First Quarter 2024 Financial Results on May 8, 2024
Catalyst Pharmaceuticals, Inc. announced that it will release its first quarter 2024 financial results after the market close on Wednesday, May 8, 2024.
April 22, 2024
·
3 min read
Deals
Catalyst Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
Catalyst Pharmaceuticals, Inc. (“Catalyst” or the “Company”) (Nasdaq: CPRX) announced today the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $15.00 per share.
January 5, 2024
·
4 min read
1 of 71,454
Next
